{"disease":{"id":"chikungunya-virus","name":"chikungunya virus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT07163845","title":"Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5354,"lead_sponsor_name":"Valneva Austria GmbH","has_results":false},{"nct_id":"NCT07254702","title":"Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5000,"lead_sponsor_name":"Valneva Austria GmbH","has_results":false},{"nct_id":"NCT04546724","title":"Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4128,"lead_sponsor_name":"Valneva Austria GmbH","has_results":true},{"nct_id":"NCT05072080","title":"A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3258,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT07520279","title":"Xpert® Tropical Fever Test on GeneXpert® Edge X System","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2500,"lead_sponsor_name":"Cepheid","has_results":false},{"nct_id":"NCT07347002","title":"Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1200,"lead_sponsor_name":"Valneva Austria GmbH","has_results":false},{"nct_id":"NCT03631719","title":"Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia","phase":"","overall_status":"COMPLETED","enrollment_count":834,"lead_sponsor_name":"Universidad de Antioquia","has_results":false},{"nct_id":"NCT03483961","title":"Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":445,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT05349617","title":"Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":413,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT04786444","title":"Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":409,"lead_sponsor_name":"Valneva Austria GmbH","has_results":true},{"nct_id":"NCT02562482","title":"Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT06106581","title":"A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":304,"lead_sponsor_name":"Valneva Austria GmbH","has_results":false},{"nct_id":"NCT02861586","title":"Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"Themis Bioscience GmbH","has_results":true},{"nct_id":"NCT07414524","title":"VLA1553-403 Pregnancy Surveillance Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Valneva Austria GmbH","has_results":false},{"nct_id":"NCT06859619","title":"Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":183,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT03028441","title":"Phase I Trial of Measles Vectored Chikungungya Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03325075","title":"Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT03635086","title":"Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Themis Bioscience GmbH","has_results":true},{"nct_id":"NCT07190560","title":"Against Chikungunya Virus and Neonatal Infection","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Centre Hospitalier Universitaire de la Réunion","has_results":false},{"nct_id":"NCT06669208","title":"Trial of an Inactivated Chikungunya Virus Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Najit Technologies, Inc.","has_results":false},{"nct_id":"NCT04441905","title":"Phase 1 Study of SAR440894 vs Placebo","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04909411","title":"Consequences of a Maternal-fetal Chikungunya Virus Infection","phase":"NA","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Centre Hospitalier Universitaire de la Réunion","has_results":false},{"nct_id":"NCT04455919","title":"Yoga for Chronic Chikungunya","phase":"NA","overall_status":"TERMINATED","enrollment_count":42,"lead_sponsor_name":"Centre Hospitalier Universitaire de la Guadeloupe","has_results":false},{"nct_id":"NCT03807843","title":"Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Themis Bioscience GmbH","has_results":true},{"nct_id":"NCT07394426","title":"A Phase I Study of PepGNP-ChikV in Healthy Volunteers","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Gylden Pharma Ltd","has_results":false},{"nct_id":"NCT03829384","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT02794181","title":"Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)","phase":"","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT05065983","title":"A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT06028841","title":"A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Valneva Austria GmbH","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}